|
1
|
Motzer RJ, Agarwal N, Beard C, Bhayani S,
Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes
GR, et al: Kidney cancer. J Natl Compr Canc Netw. 9:960–977. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ljungberg B, Campbell SC, Cho HY, Jacqmin
D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal
cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gudbjartsson T, Hardarson S, Petursdottir
V, Thoroddsen A, Magnusson J and Einarsson GV: Histological
subtyping and nuclear grading of renal cell carcinoma and their
implications for survival: A retrospective nation-wide study of 629
patients. Eur Urol. 48:593–600. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han S, Wang T, Jiang D, Yu Y, Wang Y, Yan
W, Xu W, Cheng M, Zhou W and Xiao J: Surgery and survival outcomes
of 30 patients with neurological deficit due to clear cell renal
cell carcinoma spinal metastases. Eur Spine J. 24:1786–1791. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Almeida M, Han L, Martin-Millan M, O'Brien
CA and Manolagas SC: Oxidative stress antagonizes Wnt signaling in
osteoblast precursors by diverting beta-catenin from T cell
factor-to Forkhead Box O-mediated transcription. J Biol Chem.
282:27298–27305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brenkman AB, van den Broek NJF, de Keizer
PLJ, van Gent DC and Burgering BM: The DNA damage repair protein
Ku70 interacts with FOXO4 to coordinate a conserved cellular stress
response. FASEB J. 24:4271–4280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roesch A, Mueller AM, Stempfl T, Moehle C,
Landthaler M and Vogt T: RBP2-H1/JARID1B is a transcriptional
regulator with a tumor suppressive potential in melanoma cells. Int
J Cancer. 122:1047–1057. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
10
|
Lu X, Wan F, Zhang H, Shi G and Ye D:
ITGA2B and ITGA8 are predictive of prognosis in clear cell renal
cell carcinoma patients. Tumour Biol. 37:253–262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paner GP, Stadler WM, Hansel DE, Montironi
R, Lin DW and Amin MB: Updates in the eighth edition of the
tumor-node-metastasis staging classification for urologic cancers.
Eur Urol: pii: S0302-2838. 2018.
|
|
12
|
Reddy OL, Cates JM, Gellert LL, Crist HS,
Yang Z, Yamashita H, Taylor JA III, Smith JA Jr, Chang SS, Cookson
MS, et al: Loss of FOXA1 drives sexually dimorphic changes in
Urothelial differentiation and is an independent predictor of poor
prognosis in bladder cancer. Am J Pathol. 185:1385–1395. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo W, Keener AL, Jing Y, Cai L, Ai J,
Zhang J, Fisher AL, Fu G and Wang Z: FOXA1 modulates EAF2
regulation of AR transcriptional activity, cell proliferation and
migration in prostate cancer cells. Prostate. 75:976–987. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng L, Qian B, Tian D, Tang T, Wan S,
Wang L, Zhu L and Geng X: FOXA1 positively regulates gene
expression by changing gene methylation status in human breast
cancer MCF-7 cells. Int J Clin Exp Pathol. 8:96–106.
2015.PubMed/NCBI
|
|
15
|
Dou C, Wang Y, Li C, Liu Z, Jia Y, Li Q,
Yang W, Yao Y, Liu Q and Tu K: MicroRNA-212 suppresses tumor growth
of human hepatocellular carcinoma by targeting FOXA1. Oncotarget.
6:13216–13228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang YA and Yu J: Current perspectives on
FOXA1 regulation of androgen receptor signaling and prostate
cancer. Genes Dis. 2:144–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gosalia N, Yang R, Kerschner JL and Harris
A: FOXA2 regulates a network of genes involved in critical
functions of human intestinal epithelial cells. Physiol Genomics.
47:290–297. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Perez-Balaguer A, Ortiz-Martínez F,
García-Martínez A, Pomares-Navarro C, Lerma E and Peiró G: FOXA2
mRNA expression is associated with relapse in patients with
triple-negative/basal-like breast carcinoma. Breast Cancer Res
Treat. 153:465–474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu C, Wang J, Shi B, Hu P, Ning B, Zhang
Q, Chen F, Chen WS, Zhang X and Xie WF: The transcription factor
FOXA2 suppresses gastric tumorigenesis in vitro and in vivo. Digest
Dis Sci. 60:109–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao YF, Zhao JY, Yue H, Hu KS, Shen H,
Guo ZG and Su XJ: FOXD1 promotes breast cancer proliferation and
chemotherapeutic drug resistance by targeting p27. Biochem Biophys
Res Commun. 456:232–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakayama S, Soejima K, Yasuda H, Yoda S,
Satomi R, Ikemura S, Terai H, Sato T, Yamaguchi N, Hamamoto J, et
al: FOXD1 expression is associated with poor prognosis in non-small
cell lung cancer. Anticancer Res. 35:261–268. 2015.PubMed/NCBI
|
|
22
|
Van der Heul-Nieuwenhuijsen L, Dits NF and
Jenster G: Gene expression of forkhead transcription factors in the
normal and diseased human prostate. BJU Int. 103:1574–1580. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ji Z, Donaldson IJ, Liu J, Hayes A, Zeef
LA and Sharrocks AD: The forkhead transcription factor FOXK2
promotes AP-1-mediated transcriptional regulation. Mol Cell Biol.
32:385–398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang G, He P, Gaedcke J, Ghadimi BM, Ried
T, Yfantis HG, Lee DH, Hanna N, Alexander HR and Hussain SP: FOXL1,
a novel candidate tumor suppressor, inhibits tumor aggressiveness
and predicts outcome in human pancreatic cancer. Cancer Res.
73:5416–5425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Robertson E, Perry C, Doherty R and
Madhusudan S: Transcriptomic profiling of Forkhead box
transcription factors in adult glioblastoma multiforme. Cancer
Genomics Proteomics. 12:103–112. 2015.PubMed/NCBI
|
|
26
|
Qin L, Wu YL, Toneff MJ, Li D, Liao L, Gao
X, Bane FT, Tien JC, Xu Y, Feng Z, et al: NCOA1 directly targets
M-CSF1 expression to promote breast cancer metastasis. Cancer Res.
74:3477–3488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De Coo RF, Buddiger P, Smeets HJ and van
Oost BA: Molecular cloning and characterization of the human
mitochondrial NADH: Oxidoreductase 10-kDa gene (NDUFV3). Genomics.
45:434–437. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim JC, Kim SY, Roh SA, Cho DH, Kim DD,
Kim JH and Kim YS: Gene expression profiling: Canonical molecular
changes and clinicopathological features in sporadic colorectal
cancers. World J Gastroenterol. 43:6662–6672. 2008. View Article : Google Scholar
|
|
29
|
Park-Hah JO, Kanno H, Kim WD and Fujii H:
A novel homozygous mutation of PKLR gene in a
pyruvate-kinase-deficient korean family. Acta Haematol.
113:208–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li P, Wong YN, Jahnke J, Pettit AR and
Doshi JA: Association of high cost sharing and targeted therapy
initiation among elderly Medicare patients with metastatic renal
cell carcinoma. Cancer Med. 1:75–86. 2018. View Article : Google Scholar
|
|
31
|
Hakimi AA, Reznik E, Lee CH, Creighton CJ,
Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, et al: An
integrated metabolic atlas of clear cell renal cell carcinoma.
Cancer Cell. 1:104–116. 2016. View Article : Google Scholar
|
